AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. INBS
  4. [D] Intelligent Bio Solutions Inc. SEC Filing

[D] Intelligent Bio Solutions Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D
Rhea-AI Filing Summary

Intelligent Bio Solutions, Inc. (INBS) filed a Form D reporting a Regulation D, Rule 506(b) offering in which the issuer raised $3,839,356. The filing shows the total amount offered equaled the amount sold, with 0 remaining to be sold. Proceeds include cash from warrant exercises and pre-payments tied to Series J warrants issued in the private placement; up to $7,688,266 could arise from future J warrant exercises if exercised after stockholder approval. The placement agent was Ladenburg Thalmann & Co. Inc., with estimated cash commissions of $345,542 and agent warrants for 101,160 common shares at an exercise price of $2.375. The offering involved 7 investors and the issuer reported a minimum investment accepted of $0.

Intelligent Bio Solutions, Inc. (INBS) ha depositato un Form D riferendo un'offerta ai sensi della Regulation D, Rule 506(b), con cui l'emittente ha raccolto $3,839,356. Il documento indica che l'importo totale offerto 猫 pari a quello venduto, con $0 rimanente da vendere. I proventi comprendono contanti derivanti dall'esercizio di warrant e anticipi collegati ai warrant Serie J emessi nella collocazione privata; fino a $7,688,266 potrebbero derivare da futuri esercizi dei warrant J se effettuati dopo l'approvazione degli azionisti. L'agente di collocamento 猫 stato Ladenburg Thalmann & Co. Inc., con commissioni in contanti stimate in $345,542 e warrant per l'agente su 101,160 azioni ordinarie a un prezzo di esercizio di $2.375. L'offerta ha coinvolto 7 investitori e l'emittente ha riportato un investimento minimo accettato di $0.

Intelligent Bio Solutions, Inc. (INBS) present贸 un Formulario D informando una oferta conforme a la Regulation D, Rule 506(b), en la que el emisor recaud贸 $3,839,356. La presentaci贸n muestra que el importe total ofertado equivale al vendido, con $0 pendiente de venta. Los ingresos incluyen efectivo por el ejercicio de warrants y pagos anticipados vinculados a los warrants Serie J emitidos en la colocaci贸n privada; hasta $7,688,266 podr铆an provenir de futuros ejercicios de los warrants J si se ejercen despu茅s de la aprobaci贸n de los accionistas. El agente colocador fue Ladenburg Thalmann & Co. Inc., con comisiones en efectivo estimadas en $345,542 y warrants del agente por 101,160 acciones ordinarias a un precio de ejercicio de $2.375. La oferta involucr贸 a 7 inversores y el emisor declar贸 una inversi贸n m铆nima aceptada de $0.

Intelligent Bio Solutions, Inc. (INBS)電� Regulation D, Rule 506(b)鞐� 霐半ジ 瓿奠嫓鞚� Form D毳� 鞝滌稖頄堨溂氅�, 頃措嫻 瓿惦鞐愳劀 氚滍枆靷姅 $3,839,356毳� 臁半嫭頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 齑� 氇 旮堨暋鞚� 韺愲Г霅� 旮堨暋瓿� 臧欖溂氅�, 韺愲Г 鞛旍暋鞚� $0鞛呺媹雼�. 靾橃瀰鞐愲姅 鞗岆煱韸� 頄夓偓搿� 鞚疙暅 順勱笀瓿� 靷觳暯鞐愳劀 氚滍枆霅� Series J 鞗岆煱韸胳檧 鞐瓣硠霅� 靹犽秷旮堨澊 韽暔霅橃柎 鞛堨溂氅�, 欤检＜ 鞀轨澑 鞚错泟 頄夓偓霅� 瓴届毎 頄ロ泟 J 鞗岆煱韸� 頄夓偓搿� 斓滊寑 $7,688,266臧� 氚滌儩頃� 靾� 鞛堨姷雼堧嫟. 氚办箻 鞐愳澊鞝勴姼電� Ladenburg Thalmann & Co. Inc.鞚措┌ 於旍爼 順勱笀 靾橃垬耄岆姅 $345,542, 鞐愳澊鞝勴姼 鞗岆煱韸鸽姅 頄夓偓臧� $2.375鞚� 氤错喌欤� 101,160欤检瀰雼堧嫟. 鞚措矆 鞓ろ嵓毵侅棎電� 7氇呾潣 韴瀽鞛愱皜 彀胳棳頄堨溂氅� 氚滍枆靷姅 斓滌唽 項堨毄 韴瀽鞎§潉 $0搿� 氤搓碃頄堨姷雼堧嫟.

Intelligent Bio Solutions, Inc. (INBS) a d茅pos茅 un Form D d茅clarant une offre en vertu de la Regulation D, Rule 506(b), au titre de laquelle l'茅metteur a lev茅 $3,839,356. Le d茅p么t indique que le montant total offert correspond au montant vendu, avec $0 restant 脿 vendre. Les produits comprennent des liquidit茅s provenant de l'exercice de warrants et des pr茅paiements li茅s aux warrants de la s茅rie J 茅mis lors du placement priv茅 ; jusqu'脿 $7,688,266 pourraient provenir d'exercices futurs des warrants J si ceux-ci sont exerc茅s apr猫s l'approbation des actionnaires. Le teneur de l'offre 茅tait Ladenburg Thalmann & Co. Inc., avec des commissions en esp猫ces estim茅es 脿 $345,542 et des warrants d'agent portant sur 101,160 actions ordinaires au prix d'exercice de $2.375. L'offre a impliqu茅 7 investisseurs et l'茅metteur a d茅clar茅 un investissement minimum accept茅 de $0.

Intelligent Bio Solutions, Inc. (INBS) hat ein Formular D eingereicht und ein Angebot gem盲脽 Regulation D, Rule 506(b) gemeldet, bei dem der Emittent $3,839,356 eingeworben hat. Die Einreichung zeigt, dass der insgesamt angebotene Betrag dem verkauften Betrag entspricht und $0 noch zum Verkauf steht. Die Erl枚se umfassen Bargeld aus der Aus眉bung von Warrants und Vorauszahlungen im Zusammenhang mit in der Privatplatzierung ausgegebenen Series J-Warrants; bis zu $7,688,266 k枚nnten aus k眉nftigen Aus眉bungen der J-Warrants entstehen, sofern diese nach der Zustimmung der Aktion盲re ausge眉bt werden. Der Platzierungsagent war Ladenburg Thalmann & Co. Inc., mit gesch盲tzten Barkommissionen in H枚he von $345,542 und Agenten-Warrants f眉r 101,160 Stammaktien zu einem Aus眉bungspreis von $2.375. Das Angebot umfasste 7 Investoren, und der Emittent gab ein akzeptiertes Mindestinvestment von $0 an.

Positive
  • Offering fully subscribed: Total offering amount of $3,839,356 was sold with $0 remaining.
  • Potential additional capital: Series J warrants could provide up to $7,688,266 in future proceeds if exercised (subject to shareholder approval).
  • Placement agent disclosed: Engagement of Ladenburg Thalmann & Co. Inc. with explicit commission and warrant terms increases transactional transparency.
Negative
  • Placement costs and dilution: Estimated cash commissions of $345,542 plus placement-agent warrants for 101,160 shares at $2.375 create immediate expense and future dilution.
  • Concentrated investor base: Only 7 investors participated, indicating concentration of ownership from this round.
  • Limited issuer disclosure: Issuer selected "Decline to Disclose" for revenue/asset ranges, reducing financial transparency.

Insights

TL;DR: INBS completed a Rule 506(b) financing that raised $3.84M, includes negotiable warrants and material placement-agent compensation.

The filing shows a completed private placement raising $3,839,356, fully subscribed. The instrument mix emphasizes options/warrants, including Series J warrants that could generate up to $7,688,266 if exercised subject to shareholder approval. Placement-agent cash commissions of $345,542 plus agent warrants for 101,160 shares at $2.375 create near-term cash costs and future dilution. With only seven investors disclosed, the capital is relatively concentrated. Overall this is a routine financing with dilutive features and contingent future proceeds, warranting monitoring of potential dilution and timing of any exercises.

TL;DR: The financing uses standard Reg D mechanics but includes contingent warrant proceeds tied to shareholder approval, affecting future capital structure.

The Form D indicates management authorized a private placement under Rule 506(b) and issued Series J warrants in connection with the inducement agreements. Future cash inflows from those warrants depend on stockholder approval before exercisability, which links governance actions to capital outcomes. The issuer also declined to disclose revenue/net-asset ranges, reducing transparency for external stakeholders. The disclosure of placement-agent compensation and agent warrants is explicit and allows stakeholders to quantify near-term dilution and agent incentives.

Intelligent Bio Solutions, Inc. (INBS) ha depositato un Form D riferendo un'offerta ai sensi della Regulation D, Rule 506(b), con cui l'emittente ha raccolto $3,839,356. Il documento indica che l'importo totale offerto 猫 pari a quello venduto, con $0 rimanente da vendere. I proventi comprendono contanti derivanti dall'esercizio di warrant e anticipi collegati ai warrant Serie J emessi nella collocazione privata; fino a $7,688,266 potrebbero derivare da futuri esercizi dei warrant J se effettuati dopo l'approvazione degli azionisti. L'agente di collocamento 猫 stato Ladenburg Thalmann & Co. Inc., con commissioni in contanti stimate in $345,542 e warrant per l'agente su 101,160 azioni ordinarie a un prezzo di esercizio di $2.375. L'offerta ha coinvolto 7 investitori e l'emittente ha riportato un investimento minimo accettato di $0.

Intelligent Bio Solutions, Inc. (INBS) present贸 un Formulario D informando una oferta conforme a la Regulation D, Rule 506(b), en la que el emisor recaud贸 $3,839,356. La presentaci贸n muestra que el importe total ofertado equivale al vendido, con $0 pendiente de venta. Los ingresos incluyen efectivo por el ejercicio de warrants y pagos anticipados vinculados a los warrants Serie J emitidos en la colocaci贸n privada; hasta $7,688,266 podr铆an provenir de futuros ejercicios de los warrants J si se ejercen despu茅s de la aprobaci贸n de los accionistas. El agente colocador fue Ladenburg Thalmann & Co. Inc., con comisiones en efectivo estimadas en $345,542 y warrants del agente por 101,160 acciones ordinarias a un precio de ejercicio de $2.375. La oferta involucr贸 a 7 inversores y el emisor declar贸 una inversi贸n m铆nima aceptada de $0.

Intelligent Bio Solutions, Inc. (INBS)電� Regulation D, Rule 506(b)鞐� 霐半ジ 瓿奠嫓鞚� Form D毳� 鞝滌稖頄堨溂氅�, 頃措嫻 瓿惦鞐愳劀 氚滍枆靷姅 $3,839,356毳� 臁半嫭頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 齑� 氇 旮堨暋鞚� 韺愲Г霅� 旮堨暋瓿� 臧欖溂氅�, 韺愲Г 鞛旍暋鞚� $0鞛呺媹雼�. 靾橃瀰鞐愲姅 鞗岆煱韸� 頄夓偓搿� 鞚疙暅 順勱笀瓿� 靷觳暯鞐愳劀 氚滍枆霅� Series J 鞗岆煱韸胳檧 鞐瓣硠霅� 靹犽秷旮堨澊 韽暔霅橃柎 鞛堨溂氅�, 欤检＜ 鞀轨澑 鞚错泟 頄夓偓霅� 瓴届毎 頄ロ泟 J 鞗岆煱韸� 頄夓偓搿� 斓滊寑 $7,688,266臧� 氚滌儩頃� 靾� 鞛堨姷雼堧嫟. 氚办箻 鞐愳澊鞝勴姼電� Ladenburg Thalmann & Co. Inc.鞚措┌ 於旍爼 順勱笀 靾橃垬耄岆姅 $345,542, 鞐愳澊鞝勴姼 鞗岆煱韸鸽姅 頄夓偓臧� $2.375鞚� 氤错喌欤� 101,160欤检瀰雼堧嫟. 鞚措矆 鞓ろ嵓毵侅棎電� 7氇呾潣 韴瀽鞛愱皜 彀胳棳頄堨溂氅� 氚滍枆靷姅 斓滌唽 項堨毄 韴瀽鞎§潉 $0搿� 氤搓碃頄堨姷雼堧嫟.

Intelligent Bio Solutions, Inc. (INBS) a d茅pos茅 un Form D d茅clarant une offre en vertu de la Regulation D, Rule 506(b), au titre de laquelle l'茅metteur a lev茅 $3,839,356. Le d茅p么t indique que le montant total offert correspond au montant vendu, avec $0 restant 脿 vendre. Les produits comprennent des liquidit茅s provenant de l'exercice de warrants et des pr茅paiements li茅s aux warrants de la s茅rie J 茅mis lors du placement priv茅 ; jusqu'脿 $7,688,266 pourraient provenir d'exercices futurs des warrants J si ceux-ci sont exerc茅s apr猫s l'approbation des actionnaires. Le teneur de l'offre 茅tait Ladenburg Thalmann & Co. Inc., avec des commissions en esp猫ces estim茅es 脿 $345,542 et des warrants d'agent portant sur 101,160 actions ordinaires au prix d'exercice de $2.375. L'offre a impliqu茅 7 investisseurs et l'茅metteur a d茅clar茅 un investissement minimum accept茅 de $0.

Intelligent Bio Solutions, Inc. (INBS) hat ein Formular D eingereicht und ein Angebot gem盲脽 Regulation D, Rule 506(b) gemeldet, bei dem der Emittent $3,839,356 eingeworben hat. Die Einreichung zeigt, dass der insgesamt angebotene Betrag dem verkauften Betrag entspricht und $0 noch zum Verkauf steht. Die Erl枚se umfassen Bargeld aus der Aus眉bung von Warrants und Vorauszahlungen im Zusammenhang mit in der Privatplatzierung ausgegebenen Series J-Warrants; bis zu $7,688,266 k枚nnten aus k眉nftigen Aus眉bungen der J-Warrants entstehen, sofern diese nach der Zustimmung der Aktion盲re ausge眉bt werden. Der Platzierungsagent war Ladenburg Thalmann & Co. Inc., mit gesch盲tzten Barkommissionen in H枚he von $345,542 und Agenten-Warrants f眉r 101,160 Stammaktien zu einem Aus眉bungspreis von $2.375. Das Angebot umfasste 7 Investoren, und der Emittent gab ein akzeptiertes Mindestinvestment von $0 an.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities
OMB APPROVAL
OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number) Previous Names
None
Entity Type
0001725430
GBS Inc.
Glucose Biosensor Systems (Greater China) Holdings, Inc.
Glucose Biosensor Systems (Greater China) Holdings, Inc.
GBS, Inc.
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other (Specify)

Name of Issuer
INTELLIGENT BIO SOLUTIONS INC.
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
X Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
INTELLIGENT BIO SOLUTIONS INC.
Street Address 1 Street Address 2
135 WEST 41ST ST. 5TH FLOOR
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
NEW YORK NEW YORK 10036 (646) 828-8258

3. Related Persons

Last Name First Name Middle Name
Simeonidis Harry
Street Address 1 Street Address 2
c/o Intelligent Bio Solutions, Inc. 135 West 41st St., 5th Floor
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Executive Officer
Last Name First Name Middle Name
Sakiris Spiro
Street Address 1 Street Address 2
c/o Intelligent Bio Solutions, Inc. 135 West 41st St., 5th Floor
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Financial Officer
Last Name First Name Middle Name
Boyages Steven
Street Address 1 Street Address 2
c/o Intelligent Bio Solutions, Inc. 135 West 41st St., 5th Floor
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Hurd Jonathan
Street Address 1 Street Address 2
c/o Intelligent Bio Solutions, Inc. 135 West 41st St., 5th Floor
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Isenberg Jason
Street Address 1 Street Address 2
c/o Intelligent Bio Solutions, Inc. 135 West 41st St., 5th Floor
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Fraser Nicola
Street Address 1 Street Address 2
c/o Intelligent Bio Solutions, Inc. 135 West 41st St., 5th Floor
City State/Province/Country ZIP/PostalCode
New York NEW YORK 10036
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture
Banking & Financial Services
Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
Pharmaceuticals
X Other Health Care
Manufacturing
AG真人官方 Estate
Commercial
Construction
REITS & Finance
Residential
Other AG真人官方 Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
Other

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range
No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
$1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
X Decline to Disclose Decline to Disclose
Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)
X Rule 506(b)
Rule 506(c)
Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2025-07-25 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
Yes X No

9. Type(s) of Securities Offered (select all that apply)

Equity Pooled Investment Fund Interests
Debt Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient
Recipient CRD Number None
Ladenburg Thalmann & Co. Inc. 000000505
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
640 5TH AVENUE, 4TH FLOOR
City State/Province/Country ZIP/Postal Code
New York NEW YORK 10019
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States		 All States
Foreign/non-US
ILLINOIS
NEVADA
NEW YORK
PENNSYLVANIA
TEXAS

13. Offering and Sales Amounts

Total Offering Amount $3,839,356 USD
or Indefinite
Total Amount Sold $3,839,356 USD
Total Remaining to be Sold $0 USD
or Indefinite

Clarification of Response (if Necessary):

Proceeds from warrant exercises & pre-payments per Inducement Ltr. Agmts. Series J Warrants for up to 4,046,456 shares issued in private placement. Up to $7,688,266 from future J Warrant exercises (if any) excluded; exercisable after stockholder approval.

14. Investors

 Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
7

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions $345,542 USD
Estimate
Finders' Fees $0 USD
Estimate

Clarification of Response (if Necessary):

In addition to the cash fees, the placement agent also received warrants to purchase 101,160 shares of common stock at an exercise price of $2.375 per share.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD
Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date
INTELLIGENT BIO SOLUTIONS INC. /s/ Spiro Sakiris Spiro Sakiris Chief Financial Officer 2025-08-11

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

Source:

FAQ

What amount did Intelligent Bio Solutions (INBS) raise in this Form D filing?

The issuer reports raising $3,839,356 in the offering.

What securities were offered in the INBS Form D notice?

The filing indicates options/warrants or rights to acquire securities were offered, including Series J warrants tied to the private placement.

Who acted as placement agent and what compensation was disclosed?

Ladenburg Thalmann & Co. Inc. was disclosed as the placement agent with estimated cash commissions of $345,542 and agent warrants for 101,160 shares at an exercise price of $2.375.

How many investors participated in the INBS offering?

The filing reports a total of 7 investors in the offering.

Are there potential future proceeds from warrants disclosed in the filing?

Yes. The filing notes up to $7,688,266 could result from future Series J warrant exercises if those warrants are exercised after stockholder approval.
Stock INBS logo
Intelligent Bio Solutions Inc

NASDAQ:INBS

INBS Rankings

#5964 Ranked by Market Cap
N/A Ranked by Dividends

INBS Latest News

Aug 15, 2025
Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies
Aug 12, 2025
Intelligent Bio Solutions to Participate in the Sidoti Micro-Cap Virtual Conference on August 20-21, 2025
Aug 7, 2025
Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum
Aug 6, 2025
Intelligent Bio Solutions Strengthens FDA 510(k) Package with New Cybersecurity and Performance Data Ahead of Planned U.S. Market Launch
Jul 30, 2025
Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator

INBS Latest SEC Filings

Aug 15, 2025
[10-K] Intelligent Bio Solutions Inc. Files Annual Report
Aug 7, 2025
[8-K] Intelligent Bio Solutions Inc. Reports Material Event
Aug 6, 2025
[8-K] Intelligent Bio Solutions Inc. Reports Material Event
Jul 28, 2025
[8-K] Intelligent Bio Solutions Inc. Reports Material Event
Jul 23, 2025
[8-K] Intelligent Bio Solutions Inc. Reports Material Event

INBS Stock Data

10.93M
7.34M
1.27%
11.96%
7.43%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
NEW YORK